158 related articles for article (PubMed ID: 21256151)
1. Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter?
Tuon FF; Rymsza AM; Penteado-Filho SR; Pilonetto M; Arend LN; Levin AS
J Infect; 2011 Mar; 62(3):246-9. PubMed ID: 21256151
[No Abstract] [Full Text] [Related]
2. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.
Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS
J Antimicrob Chemother; 2008 Jun; 61(6):1369-75. PubMed ID: 18367459
[TBL] [Abstract][Full Text] [Related]
3. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii.
Sheng WH; Liao CH; Lauderdale TL; Ko WC; Chen YS; Liu JW; Lau YJ; Wang LH; Liu KS; Tsai TY; Lin SY; Hsu MS; Hsu LY; Chang SC
Int J Infect Dis; 2010 Sep; 14(9):e764-9. PubMed ID: 20646946
[TBL] [Abstract][Full Text] [Related]
4. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.
Esterly JS; Griffith M; Qi C; Malczynski M; Postelnick MJ; Scheetz MH
Antimicrob Agents Chemother; 2011 Oct; 55(10):4844-9. PubMed ID: 21825287
[TBL] [Abstract][Full Text] [Related]
5. Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality.
Hernández-Torres A; García-Vázquez E; Gómez J; Canteras M; Ruiz J; Yagüe G
Med Clin (Barc); 2012 May; 138(15):650-5. PubMed ID: 22093403
[TBL] [Abstract][Full Text] [Related]
6. How carbapenem-resistant Acinetobacter spp. established in a newly constructed hospital.
Lu PL; Huang LY; Lian ST; Chang K; Lin CL; Hwang IJ; Chiang WG; Chen YH; Lin SF; Siu LK
Int J Antimicrob Agents; 2008 May; 31(5):463-6. PubMed ID: 18359613
[TBL] [Abstract][Full Text] [Related]
7. Risk factors and outcomes of bloodstream infections with metallo-beta-lactamase-producing Acinetobacter.
Kim YA; Choi JY; Kim CK; Kim CO; Kim MS; Choi SH; Chin BS; Han SH; Lee HS; Choi HK; Jeoung SJ; Song YG; Yum JH; Yong D; Lee K; Kim JM
Scand J Infect Dis; 2008; 40(3):234-40. PubMed ID: 17852898
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy.
Lee YT; Wang YC; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Yang YS
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674056
[TBL] [Abstract][Full Text] [Related]
9. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.
Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL
Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093
[No Abstract] [Full Text] [Related]
10. Outcomes and appropriateness of management of nosocomial Acinetobacter bloodstream infections at a teaching hospital in northeastern Malaysia.
Deris ZZ; Harun A; Shafei MN; Rahman RA; Johari MR
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):140-7. PubMed ID: 19323046
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii.
Tseng YC; Wang JT; Wu FL; Chen YC; Chie WC; Chang SC
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):181-90. PubMed ID: 17662564
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and outcomes in patients with carbapenem-resistant Acinetobacter infection.
Vitkauskiene A; Dambrauskiene A; Cerniauskiene K; Rimdeika R; Sakalauskas R
Scand J Infect Dis; 2013 Mar; 45(3):213-8. PubMed ID: 23113773
[TBL] [Abstract][Full Text] [Related]
13. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.
Suárez C; Peña C; Gavaldà L; Tubau F; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e73-8. PubMed ID: 20223693
[TBL] [Abstract][Full Text] [Related]
14. Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies.
Abbott I; Cerqueira GM; Bhuiyan S; Peleg AY
Expert Rev Anti Infect Ther; 2013 Apr; 11(4):395-409. PubMed ID: 23566149
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia.
Yang YS; Wang YC; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Lee YT
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652230
[TBL] [Abstract][Full Text] [Related]
16. Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit.
Jamal W; Salama M; Dehrab N; Al Hashem G; Shahin M; Rotimi VO
J Hosp Infect; 2009 Jul; 72(3):234-42. PubMed ID: 19493588
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia.
Metan G; Sariguzel F; Sumerkan B
Eur J Intern Med; 2009 Sep; 20(5):540-4. PubMed ID: 19712862
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Huang ST; Chiang MC; Kuo SC; Lee YT; Chiang TH; Yang SP; Ti-Yin ; Chen TL; Fung CP
J Microbiol Immunol Infect; 2012 Oct; 45(5):356-62. PubMed ID: 22575430
[TBL] [Abstract][Full Text] [Related]
19. Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.
Garnacho-Montero J; Amaya-Villar R; Ferrándiz-Millón C; Díaz-Martín A; López-Sánchez JM; Gutiérrez-Pizarraya A
Expert Rev Anti Infect Ther; 2015 Jun; 13(6):769-77. PubMed ID: 25865094
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia.
Kuo SC; Lee YT; Yang SP; Chiang MC; Lin YT; Tseng FC; Chen TL; Fung CP
Clin Microbiol Infect; 2013 Jul; 19(7):634-9. PubMed ID: 22776466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
